Market Research Logo

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceuticals & Healthcare, Global, Deal Summary
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2018
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2018
2.2.1 GlaxoSmithKline to Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion
2.2.2 Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck
2.2.3 Sanofi Prices Public Offering Notes for USD9.9 Billion
2.2.4 Platinum Equity to Acquire LifeScan from Johnson & Johnson for USD2.1 Billion
2.2.5 Valeant Pharma Prices Private Placement of 9.25% Senior Notes Due 2026 for USD1.17 Billion
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2018
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2018
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2018
3.1.1 Top M&A Deals in March 2018
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2017 - March 2018
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2018
3.2.1 Top Equity Offering Deals in March 2018
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2017 - March 2018
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2018
3.3.1 Top PE/VC Deals in March 2018
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2018
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2018
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-March 2018
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-March 2018
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2018
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2017 - March 2018
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2018
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2018
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2017 - March 2018
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2017 - March 2018
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2018
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2018
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2018
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2017 - March 2018
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2017 - March 2018
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2017 - March 2018
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2017 - March 2018
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2018
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2018
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2018
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2018
5.1.1 Oncology - Deals of the Month
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2018
5.2.1 Central Nervous System - Deals of the Month
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2018
5.3.1 Infectious Diseases - Deals of the Month
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2018
5.4.1 Cardiovascular - Deal of the Month
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2018
5.5.1 Immunology - Deals of the Month
5.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, March 2018
5.6.1 Respiratory - Deal of the Month
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, March 2018
5.7.1 Metabolic Disorders - Deals of the Month
6 Deal Summary by Geography
6.1 Pharmaceuticals & Healthcare, North America Deals, March 2018
6.1.1 North America - Deals of the Month
6.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2018
6.2.1 Europe - Deals of the Month
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2018
6.3.1 Asia-Pacific - Deals of the Month
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2018
6.4.1 Rest of the World - Deals of the Month
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2017 - March 2018
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2017 - March 2018
8 Further Information
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclosure information
8.5 Disclaimer
1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2018
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2018
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2018
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2017 - March 2018
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2018
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2018
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2017 - March 2018
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2018
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2017 - March 2018
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2018
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2017 - March 2018
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2017 - March 2018
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2018
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2017 - March 2018
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2018
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2018
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2018
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2018
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2018
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2018
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2017 - March 2018
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2017 - March 2018
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2018
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2018
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2017 - March 2018
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2017 - March 2018
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2017 - March 2018
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2017 - March 2018
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2017 - March 2018
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2018
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2017 - March 2018
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2017 - March 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report